See every side of every news story
Published loading...Updated

Cytokinetics, Incorporated (NASDAQ:CYTK) CEO Robert I. Blum Sells 15,000 Shares

Summary by modernreaders.com
Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) CEO Robert I. Blum sold 15,000 shares of the company’s stock in a transaction on Monday, March 31st. The stock was sold at an average price of $40.75, for a total transaction of $611,250.00. Following the sale, the chief executive officer now directly owns 427,629 shares in the company, valued at $17,425,881.75. This trade represents a 3.39 % decrease in their ownership of the stock. The…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

modernreaders.com broke the news in on Monday, March 31, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.